表紙
市場調查報告書

抗凝固療法的全球市場:產業趨勢·預測

Global Anticoagulation Therapy Market: Industry Trends and Forecast to 2026

出版商 Data Bridge Market Research Private Limited 商品編碼 904371
出版日期 內容資訊 英文 401 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
抗凝固療法的全球市場:產業趨勢·預測 Global Anticoagulation Therapy Market: Industry Trends and Forecast to 2026
出版日期: 2019年07月01日內容資訊: 英文 401 Pages
簡介

本報告提供全球抗凝固療法市場相關調查分析,提供市場概要,市場趨勢,各市場區隔的市場分析,各地區預測,主要企業等相關的系統性資訊。

第1章 簡介

第2章 市場區隔

第3章 市場概要

  • 促進因素
  • 阻礙因素
  • 機會
  • 課題

第4章 摘要整理

第5章 重要考察

第6章 全球抗凝固療法市場:各開發平台分析

  • 概要

第7章 全球抗凝固療法市場:不同治療

  • 概要
  • 深部靜脈血栓症 (DVT)
  • 肺動脈栓塞 (PE)
  • 動脈血栓性栓塞症 (AT)
  • 中風
  • 其他

第8章 全球抗凝固療法市場:各治療分類

  • 概要
  • 新的口服抗凝固藥 (NOAC)
  • 肝素
  • 維他命K拮抗劑
  • 其他

第9章 全球抗凝固療法市場:藥類別

  • 概要
  • bibarirujin
  • Dabigatran
  • edokisaban
  • betorikisaban
  • Rivaroxaban
  • Apixaban (凝血因子Ⅹa抑制劑)
  • enokisaparin
  • daruteparin
  • 其他

第10章 全球抗凝固療法市場:各給藥途徑

  • 概要
  • 口服
  • 注射

第11章 全球抗凝固療法市場:各治療領域

  • 概要
  • 心血管疾病
  • 腫瘤
  • 呼吸系統
  • 腎臟
  • 中樞神經系統
  • 其他

第12章 全球抗凝固療法市場:各治療

  • 概要
  • 術前
  • 術後
  • 腎臟透析
  • 心臟瓣膜置換

第13章 全球抗凝固療法市場:各類型

  • 概要
  • 學名藥
  • 品牌醫藥品

第14章 全球抗凝固療法市場:各終端用戶

  • 概要
  • 醫院
  • 診所
  • 居家醫療
  • ASC
  • 其他

第15章 全球抗凝固療法市場:各銷售管道

  • 概要
  • 醫院藥局
  • 零售藥局
  • 線上藥局

第16章 全球抗凝固療法市場:各地區

  • 概要
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第17章 全球抗凝固療法市場:企業形勢

  • 企業佔有率分析:世界
  • 企業佔有率分析:北美
  • 企業佔有率分析:歐洲
  • 企業佔有率分析:亞太地區

第18章 SWOT分析

第19章 企業簡介

  • BRISTOL-MYERS SQUIBB COMPANY
  • PFIZER INC.
  • BAYER AG
  • JOHNSON & JOHNSON SERVICES, INC.
  • SANOFI
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • ASPEN HOLDINGS
  • CIPLA INC.
  • 第一三共
  • EAGLE PHARMACEUTICALS, INC.
  • Eisai
  • ENDO PHARMACEUTICALS INC.
  • F. HOFFMANN-LA ROCHE LTD
  • FRESENIUS KABI AG
  • HIKMA PHARMACEUTICALS PLC
  • 田邊三菱製藥
  • MYLAN N.V.
  • NOVARTIS AG
  • PORTOLA PHARMACEUTICALS, INC.
  • SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO. LTD.
  • TARO PHARMACEUTICAL INDUSTRIES LTD.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.

第20章 參考文獻

第21章 詢問調查

第22章 相關調查

目錄

Global anticoagulation therapy market is projected to register a substantial CAGR of 8.3% in the forecast period of 2019 to 2026. The new market report contains data for the historic year 2017, the base year of calculation is 2018 and the forecast period is 2019 to 2026.

Market Segmentation

By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Geography (Europe, North America, Asia-Pacific, South America, Middle East and Africa)

Some of the major factors contributing to the growth of the global anticoagulation therapy market:

  • Rising prevalence of venous thromboembolism and pulmonary embolism
  • Increasing usage of NOACS as alternatives to warfarin
  • Growing number of surgeries
  • Increase in number of patients requiring lifelong anticoagulation therapy

Market Players:

The key market players for global anticoagulation therapy market are listed below:

  • Hikma Pharmaceuticals PLC
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Eisai Co., Ltd.
  • Pfizer Inc.
  • Sanofi
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Aspen Holdings
  • Shanghai Fosun Pharmaceutical(Group)Co., Ltd.
  • Cipla Inc
  • Johnson & Johnson Services, Inc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Company
  • DAIICHI SANKYO COMPANY, LIMITED
  • Eagle Pharmaceuticals, Inc
  • Endo Pharmaceuticals Inc
  • Mitsubishi Tanabe Pharma Corporation
  • Portola Pharmaceuticals, Inc.
  • Taro Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
  • 1.3 OVERVIEW OF GLOBAL ANTICOAGULATION THERAPY MARKET
  • 1.4 LIMITATIONS
  • 1.5 MARKETS COVERED

2 MARKET SEGMENTATION

  • 2.1 MARKETS COVERED
  • 2.2 GLOBAL ANTICOAGULATION THERAPY MARKET: GEOGRAPHICAL SCOPE
  • 2.3 YEARS CONSIDERED FOR THE STUDY
  • 2.4 CURRENCY AND PRICING
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL
  • 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
  • 2.7 DBMR MARKET POSITION GRID
  • 2.8 DBMR VENDOR SHARE ANALYSIS
  • 2.9 MULTIVARIATE MODELING
  • 2.10 PRODUCTS LIFELINE CURVE
  • 2.11 SECONDARY SOURCES
  • 2.12 ASSUMPTIONS

3 MARKET OVERVIEW

  • 3.1 DRIVERS
    • 3.1.1 RISING PREVALENCE OF VENOUS THROMBOEMBOLISM AND PULMONARY EMBOLISM
    • 3.1.2 INCREASING USAGE OF NOACS AS ALTERNATIVES TO WARFARIN
    • 3.1.3 GROWING NUMBER OF SURGERIES
    • 3.1.4 NUMBER OF PATIENTS REQUIRING LIFELONG ANTICOAGULATION THERAPY
  • 3.2 RESTRAINTS
    • 3.2.1 INCREASING GOVERNMENT RESTRICTION
    • 3.2.2 PRODUCT RECALLS
    • 3.2.3 HIGH COST OF DRUG DEVELOPMENT
  • 3.3 OPPORTUNITIES
    • 3.3.1 STRATEGIC INITIATIVES BY THE MARKET PLAYERS
    • 3.3.2 INCREASING DEVELOPMENTS IN BIOENGINEERING:
  • 3.4 CHALLENGES
    • 3.4.1 PATENT EXPIRY
    • 3.4.2 SIDE-EFFECTS OF HEPARIN

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

6 GLOBAL ANTICOAGULATION THERAPY MARKET, BY PIPELINE ANALYSIS

  • 6.1 OVERVIEW

7 GLOBAL ANTICOAGULATION THERAPY MARKET, BY TREATMENT

  • 7.1 OVERVIEW
  • 7.2 DEEP VEIN THROMBOSIS (DVT)
  • 7.3 PULMONARY EMBOLISM (PE)
  • 7.4 ARTERIAL THROMBOEMBOLISM (AT)
  • 7.5 STROKE
  • 7.6 OTHERS

8 GLOBAL ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC CLASS

  • 8.1 OVERVIEW
  • 8.2 NOVEL ORAL ANTICOAGULANTS (NOAC)
    • 8.2.1 FACTOR XA INHIBITORS
    • 8.2.2 DIRECT THROMBIN INHIBITORS
    • 8.2.3 ANTITHROMBIN PROTEIN THERAPEUTICS
  • 8.3 HEPARIN
    • 8.3.1 UNFRACTIONATED HEPARIN
    • 8.3.2 LOW MOLECULAR WEIGHT HEPARINS (LMWH)
    • 8.3.3 ULTRA LOW MOLECULAR WEIGHT HEPARINS (ULMWH)
  • 8.4 VITAMIN K ANTAGONISTS
    • 8.4.1 WARFARIN
    • 8.4.2 COUMARINS
  • 8.5 OTHERS

9 GLOBAL ANTICOAGULATION THERAPY MARKET, BY DRUG TYPE

  • 9.1 OVERVIEW
  • 9.2 BIVALIRUDIN
  • 9.3 DABIGATRAN
  • 9.4 EDOXABAN
  • 9.5 BETRIXABAN
  • 9.6 RIVAROXABAN
  • 9.7 APIXABAN
  • 9.8 ENOXAPARIN
  • 9.9 DALTEPARIN
  • 9.10 OTHERS

10 GLOBAL ANTICOAGULATION THERAPY MARKET, BY ROUTE OF ADMINISTRATION

  • 10.1 OVERVIEW
  • 10.2 ORAL
  • 10.3 INJECTABLE
    • 10.3.1 SUBCUTENEOUS
    • 10.3.2 INTRAVENOUS
    • 10.3.3 INTRAPERITONEAL
    • 10.3.4 OTHERS

11 GLOBAL ANTICOAGULATION THERAPY MARKET, BY THERAPEUTIC AREA

  • 11.1 OVERVIEW
  • 11.2 CARDIOVASCULAR DISEASES
    • 11.2.1 CORONARY ARTERY DISEASES
    • 11.2.2 MYOCARDIAL INFARCTION
    • 11.2.3 CARDIAC ARRHYTHMIA
  • 11.3 ONCOLOGY
  • 11.4 RESPIRATORY
  • 11.5 NEPHROLOGY
  • 11.6 CNS
  • 11.7 OTHERS

12 GLOBAL ANTICOAGULATION THERAPY MARKET, BY PROCEDURE

  • 12.1 OVERVIEW
  • 12.2 PRE-SURGICAL PROCEDURES
  • 12.3 POST SURGICAL PROCEDURES
  • 12.4 KIDNEY DIALYSIS
  • 12.5 HEART VALVE REPLACEMENT

13 GLOBAL ANTICOAGULATION THERAPY MARKET, BY TYPE

  • 13.1 OVERVIEW
  • 13.2 GENERICS
  • 13.3 BRANDED
    • 13.3.1 ELIQUIS
    • 13.3.2 XARELTO
    • 13.3.3 PRADAXA
    • 13.3.4 LOVENOX
    • 13.3.5 OTHERS

14 GLOBAL ANTICOAGULATION THERAPY MARKET, BY END USER

  • 14.1 OVERVIEW
  • 14.2 HOSPITALS
  • 14.3 CLINICS
  • 14.4 HOMECARE
  • 14.5 AMBULATORY SURGICAL CENTERS
  • 14.6 OTHERS

15 GLOBAL ANTICOAGULATION THERAPY MARKET, BY DISTRIBUTION CHANNEL

  • 15.1 OVERVIEW
  • 15.2 HOSPITAL PHARMACY
  • 15.3 RETAIL PHARMACY
  • 15.4 ONLINE PHARMACIES

16 GLOBAL ANTICOAGULATION THERAPY MARKET, BY GEOGRAPHY

  • 16.1 OVERVIEW
  • 16.2 NORTH AMERICA
    • 16.2.1 U.S.
    • 16.2.2 CANADA
    • 16.2.3 MEXICO
  • 16.3 EUROPE
    • 16.3.1 GERMANY
    • 16.3.2 FRANCE
    • 16.3.3 ITALY
    • 16.3.4 U.K.
    • 16.3.5 SPAIN
    • 16.3.6 SWITZERLAND
    • 16.3.7 RUSSIA
    • 16.3.8 NETHERLANDS
    • 16.3.9 BELGIUM
    • 16.3.10 TURKEY
    • 16.3.11 REST OF EUROPE
  • 16.4 ASIA-PACIFIC
    • 16.4.1 JAPAN
    • 16.4.2 CHINA
    • 16.4.3 SOUTH KOREA
    • 16.4.4 INDIA
    • 16.4.5 AUSTRALIA
    • 16.4.6 SINGAPORE
    • 16.4.7 THAILAND
    • 16.4.8 MALAYSIA
    • 16.4.9 INDONESIA
    • 16.4.10 PHILIPPINES
    • 16.4.11 REST OF ASIA-PACIFIC
  • 16.5 SOUTH AMERICA
    • 16.5.1 BRAZIL
    • 16.5.2 REST OF SOUTH AMERICA
  • 16.6 MIDDLE EAST AND AFRICA
    • 16.6.1 SOUTH AFRICA
    • 16.6.2 REST OF MIDDLE EAST AND AFRICA

17 GLOBAL ANTICOAGULATION THERPAY MARKET, COMPANY LANDSCAPE

  • 17.1 COMPANY SHARE ANALYSIS: GLOBAL
  • 17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
  • 17.3 COMPANY SHARE ANALYSIS: EUROPE
  • 17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

18 SWOT ANALYSIS

  • 18.1 STRENGTH
    • 18.1.1 SIGNIFICANT INCREASE IN SHARES IN THE MARKET-FOCUSED SEGMENT
    • 18.1.2 ESTABLISHED PRESENCE IN MARKET
  • 18.2 WEAKNESS
    • 18.2.1 DEPENDENCY ON THIRD-PARTY SUPPLIER
  • 18.3 OPPORTUNITY
    • 18.3.1 STRATEGIC INVESTMENTS /ACQUISITION/ PARTNERSHIPS / PRODUCT LAUNCH/ APPROVALS
  • 18.4 THREAT
    • 18.4.1 COMPLEXITY AND STRINGENT REQUIREMENTS FOR THE DRUG APPROVAL
  • 18.5 DATA BRIDGE MARKET RESEARCH ANALYSIS

19 COMPANY PROFILES

  • 19.1 BRISTOL-MYERS SQUIBB COMPANY
    • 19.1.1 COMPANY SNAPSHOT
    • 19.1.2 REVENUE ANALYSIS
    • 19.1.3 COMPANY SHARE ANALYSIS
    • 19.1.4 GEOGRAPHICAL PRESENCE
    • 19.1.5 PRODUCT PORTFOLIO
    • 19.1.6 RECENT DEVELOPMENT

  • 19.2 PFIZER INC.
    • 19.2.1 COMPANY SNAPSHOT
    • 19.2.2 REVENUE ANALYSIS
    • 19.2.3 COMPANY SHARE ANALYSIS
    • 19.2.4 GEOGRAPHICAL PRESENCE
    • 19.2.5 PRODUCT PORTFOLIO
    • 19.2.6 RECENT DEVELOPMENTS
  • 19.3 BAYER AG
    • 19.3.1 COMPANY SNAPSHOT
    • 19.3.2 REVENUE ANALYSIS
    • 19.3.3 COMPANY SHARE ANALYSIS
    • 19.3.4 GEOGRAPHICAL PRESENCE
    • 19.3.5 PRODUCT PORTFOLIO
    • 19.3.6 RECENT DEVELOPMENTS
  • 19.4 JOHNSON & JOHNSON SERVICES, INC.
    • 19.4.1 COMPANY SNAPSHOT
    • 19.4.2 REVENUE ANALYSIS
    • 19.4.3 COMPANY SHARE ANALYSIS
    • 19.4.4 GEOGRAPHICAL PRESENCE
    • 19.4.5 PRODUCT PORTFOLIO
    • 19.4.6 RECENT DEVELOPMENTS
  • 19.5 SANOFI
    • 19.5.1 COMPANY SNAPSHOT
    • 19.5.2 REVENUE ANALYSIS
    • 19.5.3 COMPANY SHARE ANALYSIS
    • 19.5.4 GEOGRAPHICAL PRESENCE
    • 19.5.5 PRODUCT PORTFOLIO
    • 19.5.6 RECENT DEVELOPMENT
  • 19.6 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 19.6.1 COMPANY SNAPSHOT
    • 19.6.2 REVENUE ANALYSIS
    • 19.6.3 GEOGRAPHICAL PRESENCE
    • 19.6.4 PRODUCT PORTFOLIO
    • 19.6.5 RECENT DEVELOPMENT
  • 19.7 ASPEN HOLDINGS
    • 19.7.1 COMPANY SNAPSHOT
    • 19.7.2 REVENUE ANALYSIS
    • 19.7.3 GEOGRAPHICAL PRESENCE
    • 19.7.4 PRODUCT PORTFOLIO
    • 19.7.5 RECENT DEVELOPMENTS
  • 19.8 CIPLA INC.
    • 19.8.1 COMPANY SNAPSHOT
    • 19.8.2 REVENUE ANALYSIS
    • 19.8.3 GEOGRAPHICAL PRESENCE
    • 19.8.4 PRODUCT PORTFOLIO
    • 19.8.5 RECENT DEVELOPMENT
  • 19.9 DAIICHI SANKYO COMPANY, LIMITED
    • 19.9.1 COMPANY SNAPSHOT
    • 19.9.2 REVENUE ANALYSIS
    • 19.9.3 GEOGRAPHICAL PRESENCE
    • 19.9.4 PRODUCT PORTFOLIO
    • 19.9.5 RECENT DEVELOPMENTS
  • 19.10 EAGLE PHARMACEUTICALS, INC.
    • 19.10.1 COMPANY SNAPSHOT
    • 19.10.2 REVENUE ANALYSIS
    • 19.10.3 PRODUCT PORTFOLIO
    • 19.10.4 RECENT DEVELOPMENT
  • 19.11 EISAI CO., LTD.
    • 19.11.1 COMPANY SNAPSHOT
    • 19.11.2 REVENUE ANALYSIS
    • 19.11.3 GEOGRAPHICAL PRESENCE
    • 19.11.4 PRODUCT PORTFOLIO
    • 19.11.5 RECENT DEVELOPMENT
  • 19.12 ENDO PHARMACEUTICALS INC.
    • 19.12.1 COMPANY SNAPSHOT
    • 19.12.2 REVENUE ANALYSIS
    • 19.12.3 GEOGRAPHICAL PRESENCE
    • 19.12.4 PRODUCT PORTFOLIO
    • 19.12.5 RECENT DEVELOPMENT
  • 19.13 F. HOFFMANN-LA ROCHE LTD
    • 19.13.1 COMPANY SNAPSHOT
    • 19.13.2 REVENUE ANALYSIS
    • 19.13.3 GEOGRAPHICAL PRESENCE
    • 19.13.4 PRODUCT PORTFOLIO
    • 19.13.5 RECENT DEVELOPMENT
  • 19.14 FRESENIUS KABI AG
    • 19.14.1 COMPANY SNAPSHOT
    • 19.14.2 REVENUE ANALYSIS
    • 19.14.3 GEOGRAPHICAL PRESENCE
    • 19.14.4 PRODUCT PORTFOLIO
    • 19.14.5 RECENT DEVELOPMENTS
  • 19.15 HIKMA PHARMACEUTICALS PLC
    • 19.15.1 COMPANY SNAPSHOT
    • 19.15.2 REVENUE ANALYSIS
    • 19.15.3 GEOGRAPHICAL PRESENCE
    • 19.15.4 PRODUCT PORTFOLIO
    • 19.15.5 RECENT DEVELOPMENT
  • 19.16 MITSUBISHI TANABE PHARMA CORPORATION.
    • 19.16.1 COMPANY SNAPSHOT
    • 19.16.2 REVENUE ANALYSIS
    • 19.16.3 GEOGRAPHICAL PRESENCE
    • 19.16.4 PRODUCT PORTFOLIO
    • 19.16.5 RECENT DEVELOPMENT
  • 19.17 MYLAN N.V.
    • 19.17.1 COMPANY SNAPSHOT
    • 19.17.2 REVENUE ANALYSIS
    • 19.17.3 GEOGRAPHICAL PRESENCE
    • 19.17.4 PRODUCT PORTFOLIO
    • 19.17.5 RECENT DEVELOPMENTS
  • 19.18 NOVARTIS AG
    • 19.18.1 COMPANY SNAPSHOT
    • 19.18.2 REVENUE ANALYSIS
    • 19.18.3 GEOGRAPHICAL PRESENCE
    • 19.18.4 PRODUCT PORTFOLIO
    • 19.18.5 RECENT DEVELOPMENT
  • 19.19 PORTOLA PHARMACEUTICALS, INC.
    • 19.19.1 COMPANY SNAPSHOT
    • 19.19.2 REVENUE ANALYSIS
    • 19.19.3 PRODUCT PORTFOLIO
    • 19.19.4 RECENT DEVELOPMENT
  • 19.20 SHANGHAI FOSUN PHARMACEUTICAL (GROUP)CO. LTD.
    • 19.20.1 COMPANY SNAPSHOT
    • 19.20.2 REVENUE ANALYSIS
    • 19.20.3 GEOGRAPHICAL PRESENCE
    • 19.20.4 PRODUCT PORTFOLIO
    • 19.20.5 RECENT DEVELOPMENT

  • 19.21 TARO PHARMACEUTICAL INDUSTRIES LTD.
    • 19.21.1 COMPANY SNAPSHOT
    • 19.21.2 REVENUE ANALYSIS
    • 19.21.3 GEOGRAPHICAL PRESENCE
    • 19.21.4 PRODUCT PORTFOLIO
    • 19.21.5 RECENT DEVELOPMENT
  • 19.22 TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • 19.22.1 COMPANY SNAPSHOT
    • 19.22.2 REVENUE ANALYSIS
    • 19.22.3 GEOGRAPHICAL PRESENCE
    • 19.22.4 PRODUCT PORTFOLIO
    • 19.22.5 RECENT DEVELOPMENTS

20 REFERENCES

21 QUESTIONNAIRE

22 RELATED REPORTS

LIST OF FIGURES

  • FIGURE 1 GLOBAL ANTICOAGULATION THERAPY MARKET
  • FIGURE 2 GLOBAL ANTICOAGULATION THERAPY MARKET: DATA VALIDATION MODEL
  • FIGURE 3 GLOBAL ANTICOAGULATION THERAPY MARKET: DROC ANALYSIS
  • FIGURE 4 GLOBAL ANTICOAGULATION THERAPY MARKET: GLOBAL VS REGIONAL ANALYSIS
  • FIGURE 5 GLOBAL ANTICOAGULATION THERAPY MARKET: COMPANY RESEARCH ANALYSIS
  • FIGURE 6 GLOBAL ANTICOAGULATION THERAPY MARKET: INTERVIEW DEMOGRAPHICS
  • FIGURE 7 GLOBAL ANTICOAGULATION THERAPY MARKET: DBMR MARKET POSITION GRID
  • FIGURE 1 GLOBAL ANTICOAGULATION THERAPY MARKET: DBMR VENDOR SHARE ANALYSIS
  • FIGURE 2 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL ANTICOAGULATION THERAPY MARKET
  • FIGURE 3 GLOBAL ANTICOAGULATION THERAPY MARKET: SEGMENTATION
  • FIGURE 4 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE GLOBAL ANTICOAGULATION THERAPY MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE INCREASING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 5 RISING PREVALENCE OF VENOUS THROMBOEMBOLISM AND PULMONARY EMBOLISM AND GROWING NUMBER OF SURGERIES ARE EXPECTED TO DRIVE THE GLOBAL ANTICOAGULATION THERAPY MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 6 DEEP VEIN THROMBOSIS(DVT) IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ANTICOAGULATION THERAPY MARKET IN 2019 & 2026
  • FIGURE 7 ASIA-PACIFIC IS THE MAXIMUM GROWING AND MOST PROFITABLE REVENUE POCKETS FOR GLOBAL ANTICOAGULATION THERAPY MARKET IN THE FORECAST PERIOD OF 2019 TO 2026
  • FIGURE 8 GLOBAL ANTICOAGULATION THERAPY MARKET: BY TREATMENT, 2018
  • FIGURE 9 GLOBAL ANTICOAGULATION THERAPY MARKET: BY THERAPEUTIC CLASS, 2018
  • FIGURE 10 GLOBAL ANTICOAGULATION THERAPY MARKET: BY DRUG TYPE, 2018
  • FIGURE 11 GLOBAL ANTICOAGULATION THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2018
  • FIGURE 12 GLOBAL ANTICOAGULATION THERAPY MARKET: BY THERAPEUTIC AREA, 2018
  • FIGURE 13 GLOBAL ANTICOAGULATION THERAPY TREATMENT MARKET: BY PROCEDURE, 2018
  • FIGURE 14 GLOBAL ANTICOAGULATION THERAPY MARKET: BY TYPE, 2018
  • FIGURE 15 GLOBAL ANTICOAGULATION THERAPY MARKET: BY END USER, 2018
  • FIGURE 16 GLOBAL ANTICOAGULATION THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2018
  • FIGURE 17 GLOBAL ANTICOAGULATION THERAPY MARKET: SNAPSHOT (2018)
  • FIGURE 18 GLOBAL ANTICOAGULATION THERAPY MARKET: BY GEOGRAPHY (2018)
  • FIGURE 19 GLOBAL ANTICOAGULATION THERAPY MARKET: BY GEOGRAPHY (2018 & 2026)
  • FIGURE 20 GLOBAL ANTICOAGULATION THERAPY MARKET, BY GEOGRAPHY (2018 & 2026)
  • FIGURE 21 GLOBAL ANTICOAGULATION THERAPY MARKET, BY TYPE (2018 - 2026)
  • FIGURE 22 NORTH AMERICA ANTICOAGULATION THERAPY MARKET: SNAPSHOT (2018)
  • FIGURE 23 NORTH AMERICA ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2018)
  • FIGURE 24 NORTH AMERICA ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2019 & 2026)
  • FIGURE 25 NORTH AMERICA ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 26 NORTH AMERICA ANTICOAGULATION THERAPY MARKET: BY TREATMENT (2019-2026)
  • FIGURE 27 EUROPE ANTICOAGULATION THERAPY MARKET: SNAPSHOT (2018)
  • FIGURE 28 EUROPE ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2018)
  • FIGURE 29 EUROPE ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2019)
  • FIGURE 30 EUROPE ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 31 EUROPE ANTICOAGULATION THERAPY MARKET: BY TREATMENT (2019-2026)
  • FIGURE 32 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET: SNAPSHOT (2018)
  • FIGURE 33 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2018)
  • FIGURE 34 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2019)
  • FIGURE 35 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 36 ASIA-PACIFIC ANTICOAGULATION THERAPY MARKET: BY TREATMENT (2019-2026)
  • FIGURE 37 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET: SNAPSHOT (2018)
  • FIGURE 38 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2018)
  • FIGURE 39 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2019)
  • FIGURE 40 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 41 SOUTH AMERICA ANTICOAGULATION THERAPY MARKET: BY TREATMENT (2019-2026)
  • FIGURE 42 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET: SNAPSHOT (2018)
  • FIGURE 43 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2018)
  • FIGURE 44 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2019)
  • FIGURE 45 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET: BY COUNTRY (2018 & 2026)
  • FIGURE 46 MIDDLE EAST AND AFRICA ANTICOAGULATION THERAPY MARKET: BY TREATMENT (2019-2026)
  • FIGURE 47 GLOBAL ANTICOAGULATION THERPAY MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 48 NORTH AMERICA ANTICOAGULATION THERPAY MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 49 EUROPE ANTICOAGULATION THERPAY MARKET: COMPANY SHARE 2018 (%)
  • FIGURE 50 ASIA-PACIFIC ANTICOAGULATION THERPAY MARKET: COMPANY SHARE 2018 (%)
Back to Top